Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma

21 Oct 2018

Abstract excerpt

Multiple myeloma (MM) is an incurable hematological malignancy caused by accumulation of abnormal clonal plasma cells. Despite the recent development of novel therapies, relapse of MM eventually occurs as a result of a remaining population of drug-resistant myeloma stem cells. Side population (SP) cells show cancer stem cell-like characteristics in MM; thus, targeting these cells is a promising strategy to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Microtubule and mitosis dynamics
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30343511
DOI: 10.1111/cas.13840

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myelomaPMID 30343511Read ↗

[EZH2 is therapeutic target for personalized treatment in multiple myeloma].Semantic proximity Read ↗

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.Semantic proximity Read ↗

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functionsSemantic proximity Read ↗

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Semantic proximity Read ↗

Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma.Semantic proximity Read ↗

Multiple Myeloma: A Paradigm for Translation of the Cancer Stem Cell HypothesisSemantic proximity Read ↗

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effectsSemantic proximity Read ↗

Role of EZH2 in cancer stem cells: from biological insight to a therapeutic targetSemantic proximity Read ↗

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent mannerSemantic proximity Read ↗

Multiple myeloma cancer stem cells.Semantic proximity Read ↗

Myeloma-specific superenhancers affect genes of biological and clinical relevance in myelomaSemantic proximity Read ↗

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.